| Index | - | P/E | 25.75 | EPS (ttm) | 6.66 | Insider Own | 0.00% | Shs Outstand | 1.55B | Perf Week | 3.68% |
| Market Cap | 265.96B | Forward P/E | 15.04 | EPS next Y | 11.40 | Insider Trans | -38.11% | Shs Float | 1.54B | Perf Month | 4.21% |
| Enterprise Value | 293.20B | PEG | 2.13 | EPS next Q | - | Inst Own | 81.56% | Short Float | 0.17% | Perf Quarter | 1.09% |
| Income | 10.45B | P/S | 4.33 | EPS this Y | 11.90% | Inst Trans | 0.00% | Short Ratio | 0.77 | Perf Half Y | -9.62% |
| Sales | 61.37B | P/B | 5.29 | EPS next Y | 11.27% | ROA | 8.96% | Short Interest | 2.62M | Perf YTD | -2.28% |
| Book/sh | 32.44 | P/C | 53.60 | EPS next 5Y | 12.09% | ROE | 21.68% | 52W High | 212.71 -19.38% | Perf Year | 2.77% |
| Cash/sh | 3.20 | P/FCF | 31.55 | EPS past 3/5Y | 45.80% 21.80% | ROIC | 12.69% | 52W Low | 153.40 11.79% | Perf 3Y | 31.02% |
| Dividend Est. | 2.12 (1.24%) | EV/EBITDA | 14.17 | Sales past 3/5Y | 9.82% 17.15% | Gross Margin | 79.27% | Volatility | 1.59% 1.85% | Perf 5Y | 44.62% |
| Dividend TTM | 3.23 (1.88%) | EV/Sales | 4.78 | EPS Y/Y TTM | 48.00% | Oper. Margin | 22.69% | ATR (14) | 3.72 | Perf 10Y | 183.22% |
| Dividend Ex-Date | Aug 07, 2026 | Quick Ratio | 0.67 | Sales Y/Y TTM | 13.49% | Profit Margin | 17.02% | RSI (14) | 62.54 | Recom | 2.63 |
| Dividend Gr. 3/5Y | 2.86% 2.46% | Current Ratio | 0.89 | EPS Q/Q | 20.64% | SMA20 | 5.43% | Beta | 0.33 | Target Price | 186.67 |
| Payout | 47.05% | Debt/Eq | 0.60 | Sales Q/Q | 6.41% | SMA50 | 5.16% | Rel Volume | 1.07 | Prev Close | 172.57 |
| Employees | 96,100 | LT Debt/Eq | 0.54 | Earnings | Oct 30 | SMA200 | -4.94% | Avg Volume | 3.43M | Price | 171.49 |
| IPO Date | May 12, 1993 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.21% -0.33% | Net Debt/EBITDA | 1.34 | Volume | 3,666,045 | Change | -0.63% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Dec-10-25 | Reiterated | HSBC | Buy | $95 → $108 |
| Dec-03-25 | Reiterated | Morgan Stanley | Overweight | $93 → $103 |
| Jul-09-25 | Reiterated | Berenberg Bank | $93 → $97 | |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy | |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral | |
| Nov-13-24 | Reiterated | BMO Capital | Outperform | $89 → $88 |
| Sep-11-24 | Reiterated | BMO Capital | Outperform | $82 → $89 |
| Sep-11-24 | Upgrade | Erste Group | Hold → Buy | |
| May-30-24 | Reiterated | Argus Research | Buy | $85 |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 61,366 | 58,739 | 54,073 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 11,120 | 10,633 | 10,207 | — | — | — | — | — | — | |
| Gross Profit | 50,246 | 48,106 | 43,866 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 21,735 | 20,512 | 20,224 | — | — | — | — | — | — | |
| Research and Development | 15,070 | 14,232 | 13,583 | — | — | — | — | — | — | |
| Other Operating Expense | -530 | -381 | 56 | — | — | — | — | — | — | |
| Operating Income | 13,971 | 13,743 | 10,003 | — | — | — | — | — | — | |
| Interest Expense | 1,734 | 1,694 | 1,682 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 349 | 353 | 370 | — | — | — | — | — | — | |
| Net Income Before Taxes | 12,586 | 12,402 | 8,691 | — | — | — | — | — | — | |
| Income Taxes | 2,133 | 2,169 | 1,650 | — | — | — | — | — | — | |
| Consolidated Net Income | 10,446 | 10,255 | 7,035 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 10,453 | 10,233 | 7,041 | — | — | — | — | — | — | |
| Net Income | 10,446 | 10,255 | 7,035 | — | — | — | — | — | — | |
| EPS (Recurring) | 6.72 | 6.60 | 4.54 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 6.72 | 6.60 | 4.54 | — | — | — | — | — | — | |
| EPS (Diluted) | 6.66 | 6.54 | 4.50 | — | — | — | — | — | — | |
| EBITDA | 20,695 | 19,829 | 15,438 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 25.75 | 26.83 | 28.89 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.33 | 4.63 | 3.73 | — | — | — | — | — | — | |
| Gross Margin | 81.88 | 81.90 | 81.12 | — | — | — | — | — | — | |
| Operating Margin | 22.77 | 23.40 | 18.50 | — | — | — | — | — | — | |
| Net Margin | 17.02 | 17.46 | 13.01 | — | — | — | — | — | — | |
| Shares Outstanding | 1,551 | 1,550 | 1,550 | — | — | — | — | — | — | |
| Market Capitalization | 265,981 | 272,025 | 201,500 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sharma Mani | See Remarks | Aug 08 '26 | Buy | 160.57 | 20 | 3,249 | 19,288 | Sep 11 |
| Sharma Mani | See Remarks | May 20 '26 | Sale | 185.78 | 11,893 | 2,209,482 | 19,262 | May 22 |